Trinity Biotech Debt 2024

Trinity Biotech Aktienanalyse

What does Trinity Biotech do?

Trinity Biotech PLC is a company specialized in the development, production, and marketing of diagnostic tests for infectious diseases, autoimmune diseases, and cancer. The company was founded in 1992 by Ronan O'Caoimh, an experienced manager in the diagnostics industry. Trinity Biotech has continuously expanded its business and is now recognized as one of the leading companies in the industry worldwide. Its business strategy is based on the development and marketing of diagnostic tests utilizing the latest technology and research. The company has a strong focus on continuous research and development of new products and technologies. Trinity Biotech operates in three main divisions: infectious diseases, autoimmune diseases, and cancer diagnostics. The company offers tests for various infectious diseases such as HIV, hepatitis, and tuberculosis in the infectious diseases division. The autoimmune diseases division develops and produces diagnostic tests for autoimmune diseases such as lupus, rheumatoid arthritis, and Sjögren's syndrome. The cancer diagnostics division offers tests for various types of cancer such as breast cancer, prostate cancer, and colon cancer. Trinity Biotech's key products include the Uni-Gold HIV test, the TrinScreen Hepatitis C test, and the Uni-Gold S. pneumoniae test. These tests are highly accurate and reliable diagnostic tools used by clinics and laboratories worldwide. Trinity Biotech has a global presence with offices in North America, Europe, Asia, and the Middle East. The company is committed to providing its customers with the best possible diagnostic technology and support. Overall, Trinity Biotech is a renowned company in the diagnostics industry focused on developing innovative diagnostic tests for infectious diseases, autoimmune diseases, and cancer. With its strong R&D department, wide range of products, and global presence, Trinity Biotech will continue to play a leading role in the industry. Trinity Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Trinity Biotech's Debt Structure

Trinity Biotech's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Trinity Biotech's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Trinity Biotech’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Trinity Biotech’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Trinity Biotech stock

What is the debt of Trinity Biotech this year?

Trinity Biotech has a debt level of 63.74 USD this year.

What was the debt of Trinity Biotech compared to the previous year?

The debt of Trinity Biotech has increased by -2.87% compared to the previous year dropped.

What are the consequences of high debt for investors in Trinity Biotech?

High debt can pose a risk for investors of Trinity Biotech, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Trinity Biotech?

Low debt means that Trinity Biotech has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Trinity Biotech affect the company?

An increase in debt of Trinity Biotech can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Trinity Biotech affect the company?

A reduction in debt of Trinity Biotech can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Trinity Biotech?

Some factors that can influence the debt of Trinity Biotech include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Trinity Biotech so important for investors?

The debts of Trinity Biotech are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Trinity Biotech take to change the debt?

To change the debt, Trinity Biotech can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Trinity Biotech pay?

Over the past 12 months, Trinity Biotech paid a dividend of 0.22 USD . This corresponds to a dividend yield of about 19.73 %. For the coming 12 months, Trinity Biotech is expected to pay a dividend of -0.23 USD.

What is the dividend yield of Trinity Biotech?

The current dividend yield of Trinity Biotech is 19.73 %.

When does Trinity Biotech pay dividends?

Trinity Biotech pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Trinity Biotech?

Trinity Biotech paid dividends every year for the past 0 years.

What is the dividend of Trinity Biotech?

For the upcoming 12 months, dividends amounting to -0.23 USD are expected. This corresponds to a dividend yield of -21.07 %.

In which sector is Trinity Biotech located?

Trinity Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Trinity Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Trinity Biotech from 7/1/2015 amounting to 0.22 USD, you needed to have the stock in your portfolio before the ex-date on 6/5/2015.

When did Trinity Biotech pay the last dividend?

The last dividend was paid out on 7/1/2015.

What was the dividend of Trinity Biotech in the year 2023?

In the year 2023, Trinity Biotech distributed 0 USD as dividends.

In which currency does Trinity Biotech pay out the dividend?

The dividends of Trinity Biotech are distributed in USD.